To further explore the utility of WT1 TED2 split to target WT1-HLA-A*02:01+ tumors, we obtained WT1-HLA-A*02:01+ primary AML cells, given that primary AML cells have more physiological expression of WT1-HLA-A*02:01 than tumor cell lines. This evidence concerns the gene WT1 and acute myeloid leukemia.